![]() | |
![]() | |
Combination of | |
---|---|
Estradiol cypionate | Estrogen |
Testosterone cypionate | Androgen; Anabolic steroid |
Clinical data | |
Trade names | Depo-Testadiol, Femovirin, depAndrogyn, others |
Other names | EC/TC |
Routes of administration | Intramuscular injection |
Identifiers | |
CAS Number |
Estradiol cypionate/testosterone cypionate (EC/TC), sold under the brand names Depo-Testadiol and Femovirin among others, is an injectable combination medication of estradiol cypionate (EC), an estrogen, and testosterone cypionate (TC), an androgen/ anabolic steroid, which is used in menopausal hormone therapy for women. [1] It is specifically indicated for the treatment of moderate-to-severe vasomotor symptoms (i.e., hot flashes), but can also be used for other estrogen indications in women. [1] The medication has also been used to suppress lactation in postpartum women. [2]
Depo-Testadiol was provided in the form of 10 mL vials containing 2 mg/mL EC and 50 mg/mL TC in an oil solution and was administered by intramuscular injection once every 4 weeks. [1] Conversely, Femovirin was provided in the form of 1 mL ampoules containing 3.5 mg/mL EC (2.4 mg/mL free estradiol) and 90 mg/mL TC (62.9 mg/mL free testosterone) in an oil solution and was administered by intramuscular injection once every 4 to 6 weeks. [3]
[4] [5] [6] [7] The elimination half-life of EC in oil by intramuscular injection is approximately 5 days, while the elimination half-life of TC in oil by intramuscular injection is approximately 8 days. [1] EC/TP reportedly has a duration of about 21 days. [8]
EC/TC likely poses a considerably increased risk of endometrial hyperplasia and cancer in women with intact uteruses (i.e., women who are not hysterectomized) if it is not combined with a progestogen. [1] This is due to the EC component. [1] The concomitant use of a progestogen will abolish such risks. [1] The medication can also cause masculinization, such as acne, deepened voice, hirsutism, and increased sex drive, due to its TC component. [1] Some of these masculinizing symptoms, such as voice deepening, can be irreversible. [1]
Depo-Testadiol was introduced for medical use in 1954, [9] while Femovirin was introduced for medical use in 1956. [10] An oral tablet product with the same brand name of Femovirin, containing ethinylestradiol and methyltestosterone, was marketed in 1958, and should not be confused with the injectable Femovirin. [11] [4] Depo-Testadiol was discontinued in the United States by 2013. [12] Both Depo-Testadiol and Femovirin have been discontinued in most other countries, but formulations of EC/TC under other brand names continue to be marketed in Taiwan. [13] [14] [15]
Route | Medication | Major brand names | Form | Dosage |
---|---|---|---|---|
Oral | Testosterone undecanoate | Andriol, Jatenzo | Capsule | 40–80 mg 1x/1–2 days |
Methyltestosterone | Metandren, Estratest | Tablet | 0.5–10 mg/day | |
Fluoxymesterone | Halotestin | Tablet | 1–2.5 mg 1x/1–2 days | |
Normethandronea | Ginecoside | Tablet | 5 mg/day | |
Tibolone | Livial | Tablet | 1.25–2.5 mg/day | |
Prasterone ( DHEA)b | – | Tablet | 10–100 mg/day | |
Sublingual | Methyltestosterone | Metandren | Tablet | 0.25 mg/day |
Transdermal | Testosterone | Intrinsa | Patch | 150–300 μg/day |
AndroGel | Gel, cream | 1–10 mg/day | ||
Vaginal | Prasterone ( DHEA) | Intrarosa | Insert | 6.5 mg/day |
Injection | Testosterone propionatea | Testoviron | Oil solution | 25 mg 1x/1–2 weeks |
Testosterone enanthate | Delatestryl, Primodian Depot | Oil solution | 25–100 mg 1x/4–6 weeks | |
Testosterone cypionate | Depo-Testosterone, Depo-Testadiol | Oil solution | 25–100 mg 1x/4–6 weeks | |
Testosterone isobutyratea | Femandren M, Folivirin | Aqueous suspension | 25–50 mg 1x/4–6 weeks | |
Mixed testosterone esters | Climacterona | Oil solution | 150 mg 1x/4–8 weeks | |
Omnadren, Sustanon | Oil solution | 50–100 mg 1x/4–6 weeks | ||
Nandrolone decanoate | Deca-Durabolin | Oil solution | 25–50 mg 1x/6–12 weeks | |
Prasterone enanthatea | Gynodian Depot | Oil solution | 200 mg 1x/4–6 weeks | |
Implant | Testosterone | Testopel | Pellet | 50–100 mg 1x/3–6 months |
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template. |
![]() | |
![]() | |
Combination of | |
---|---|
Estradiol cypionate | Estrogen |
Testosterone cypionate | Androgen; Anabolic steroid |
Clinical data | |
Trade names | Depo-Testadiol, Femovirin, depAndrogyn, others |
Other names | EC/TC |
Routes of administration | Intramuscular injection |
Identifiers | |
CAS Number |
Estradiol cypionate/testosterone cypionate (EC/TC), sold under the brand names Depo-Testadiol and Femovirin among others, is an injectable combination medication of estradiol cypionate (EC), an estrogen, and testosterone cypionate (TC), an androgen/ anabolic steroid, which is used in menopausal hormone therapy for women. [1] It is specifically indicated for the treatment of moderate-to-severe vasomotor symptoms (i.e., hot flashes), but can also be used for other estrogen indications in women. [1] The medication has also been used to suppress lactation in postpartum women. [2]
Depo-Testadiol was provided in the form of 10 mL vials containing 2 mg/mL EC and 50 mg/mL TC in an oil solution and was administered by intramuscular injection once every 4 weeks. [1] Conversely, Femovirin was provided in the form of 1 mL ampoules containing 3.5 mg/mL EC (2.4 mg/mL free estradiol) and 90 mg/mL TC (62.9 mg/mL free testosterone) in an oil solution and was administered by intramuscular injection once every 4 to 6 weeks. [3]
[4] [5] [6] [7] The elimination half-life of EC in oil by intramuscular injection is approximately 5 days, while the elimination half-life of TC in oil by intramuscular injection is approximately 8 days. [1] EC/TP reportedly has a duration of about 21 days. [8]
EC/TC likely poses a considerably increased risk of endometrial hyperplasia and cancer in women with intact uteruses (i.e., women who are not hysterectomized) if it is not combined with a progestogen. [1] This is due to the EC component. [1] The concomitant use of a progestogen will abolish such risks. [1] The medication can also cause masculinization, such as acne, deepened voice, hirsutism, and increased sex drive, due to its TC component. [1] Some of these masculinizing symptoms, such as voice deepening, can be irreversible. [1]
Depo-Testadiol was introduced for medical use in 1954, [9] while Femovirin was introduced for medical use in 1956. [10] An oral tablet product with the same brand name of Femovirin, containing ethinylestradiol and methyltestosterone, was marketed in 1958, and should not be confused with the injectable Femovirin. [11] [4] Depo-Testadiol was discontinued in the United States by 2013. [12] Both Depo-Testadiol and Femovirin have been discontinued in most other countries, but formulations of EC/TC under other brand names continue to be marketed in Taiwan. [13] [14] [15]
Route | Medication | Major brand names | Form | Dosage |
---|---|---|---|---|
Oral | Testosterone undecanoate | Andriol, Jatenzo | Capsule | 40–80 mg 1x/1–2 days |
Methyltestosterone | Metandren, Estratest | Tablet | 0.5–10 mg/day | |
Fluoxymesterone | Halotestin | Tablet | 1–2.5 mg 1x/1–2 days | |
Normethandronea | Ginecoside | Tablet | 5 mg/day | |
Tibolone | Livial | Tablet | 1.25–2.5 mg/day | |
Prasterone ( DHEA)b | – | Tablet | 10–100 mg/day | |
Sublingual | Methyltestosterone | Metandren | Tablet | 0.25 mg/day |
Transdermal | Testosterone | Intrinsa | Patch | 150–300 μg/day |
AndroGel | Gel, cream | 1–10 mg/day | ||
Vaginal | Prasterone ( DHEA) | Intrarosa | Insert | 6.5 mg/day |
Injection | Testosterone propionatea | Testoviron | Oil solution | 25 mg 1x/1–2 weeks |
Testosterone enanthate | Delatestryl, Primodian Depot | Oil solution | 25–100 mg 1x/4–6 weeks | |
Testosterone cypionate | Depo-Testosterone, Depo-Testadiol | Oil solution | 25–100 mg 1x/4–6 weeks | |
Testosterone isobutyratea | Femandren M, Folivirin | Aqueous suspension | 25–50 mg 1x/4–6 weeks | |
Mixed testosterone esters | Climacterona | Oil solution | 150 mg 1x/4–8 weeks | |
Omnadren, Sustanon | Oil solution | 50–100 mg 1x/4–6 weeks | ||
Nandrolone decanoate | Deca-Durabolin | Oil solution | 25–50 mg 1x/6–12 weeks | |
Prasterone enanthatea | Gynodian Depot | Oil solution | 200 mg 1x/4–6 weeks | |
Implant | Testosterone | Testopel | Pellet | 50–100 mg 1x/3–6 months |
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template. |